On April 23, Scandinavian Tobacco Group A/S reached an agreement on the terms and conditions of the acquisition of almost all of the assets of XQS International AB, a Swedish company. The transaction is expected to be completed soon.
The transaction value includes a prepayment and a profit target agreement. Assuming all targets are met, the total acquisition price will be approximately DKK 150 million, which will be fully financed through cash and debt.
XQS is involved in the nicotine pouch business, with their products mainly sold in Sweden. In 2022, XQS reported a net sales revenue of approximately 50 million Danish kroner (equivalent to 50.88 million yuan) with an EBITDA profit margin in the single digits. Their total sales volume amounted to 3 million cans.
Scandinavian Tobacco Group specializes in the manufacture of cigars and pipe tobacco, with its headquarters located in Copenhagen, Denmark. The company produces 4 billion cigars and 5,000 tons of fine-cut tobacco annually. It also has over 200 investments globally and locally, including notable brands such as Cohiba, CAO, and Macanudo.
Further Reading:
Scandinavian Tobacco Group A/S plans to increase its stock buyback to a total value of up to 1 billion Danish kroner.
Scandinavian Tobacco Group has concluded its stock buyback.
The Scandinavian Tobacco Group is set to acquire Alec Bradley Cigars.
References:
Scandinavian Tobacco Group A/S has acquired the brand XQS.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
